Index

Note: Page numbers of article titles are in **bold face** type.

AFIBRINOGENAEMIA, 172
  congenital, clinical observations in, 173–175
  platelets in, 174–175
  thrombosis and thromboembolism in, 175
Alpha$_1$-antitrypsin, 20
Alpha$_2$-antitrypsin, 20
  -macroglobulin, 20
Antibodies to blood coagulation factors, **207–214**
Antithrombin III (AT III), 16–20
  action of, on other clotting factors, 19
  hereditary deficiencies of, 19–20
  mode of action of, 17–19

BLOOD clotting–
  factors, 4
  natural inhibitors of, 15–22
Blood coagulation, *see* Coagulation

CHRISTMAS disease, heterogeneity of, 34–35
Christmas disease and haemophilia—
  prevalence of, 96–97
  recent advances in the management of, **95–114**
CIg and factor XIII, 13
Clinico-pathological correlations in blood coagulation, 21–22
Clotting factors, 4
Coagulation—
  cascade mechanism of, **5**
  chemistry of, **3–30**
  contact phase of, 6–9
  defects, congenital—
    laboratory diagnosis of, **79–94**
    treatment of, therapeutic materials used in, **183–206**
  factor concentrates—
    produced by major manufacturers, 202–204
    provision of, 110–113
  factors, 184, *see also* individual factors
    antibodies to, **207–214**
    inhibitors to other, 211–212
Coagulation (*continued*)
  middle phase of, 9–12
  pathway—
    extrinsic, 80, 88
    intrinsic, 80
  role of vitamin K in, 14–15
  terminal phase of, 12–13
Concentrates containing factors IX, II, X, and VII, 194–198
Congenital abnormalities of fibrinogen, **169–181**
Congenital coagulation defects—
  activated partial thromboplastin time in, 81–82
  bleeding time and, 81
  collection of blood for plasma in, 81
  history and examination of, 79
  laboratory diagnosis of, **79–94**
  one-stage prothrombin time in, 82
  routine screening tests for, 80–92
  screening tests in the diagnosis of, 80
  thrombin clotting time in, 82
Congenital deficiencies of coagulation factors, therapeutic materials in, **183–206**
Contact factors, 90–92
Contact phase of coagulation, 6–9

DYSFIBRINOGENAEMIA, 173

FACTOR II, 199
Factor V, 90, 200
  and factor X, 11–12
Factor VII, 89–90, 199
Factor VIII, 36–47
  active, subunits of, 43–45
  activity—
    assays of, 83–84
    in cryoprecipitate, 97–98
    neurological stress and endocrine factors in, 64–66
    physical exertion and adrenergic stimuli in, 64
    in plasma, 97
    recovery of, from various preparations, 98

Factor VIII (*continued*)
stability of, 41–42
antibodies to, 109–110
biosynthesis of, **53–77**
chemical structure of, 38–41
coagulant activity, 44
commercial, 98
concentrates, 186–193
freeze-dried, 187–191
hazards associated with the use of, 193
schemes for production of, 188
single-donor or small-pool cryoprecipitate, 186–187
in von Willebrand's disease, 193
cost of, to the nation, 111–113
2,3-diphosphoglycerate and, 66–67
endothelial cells and, 59
and factor IX, 9–10
interaction of, 31–32
human blood vessels and, 58
immunological studies on synthesis, 57–58
inhibitors to, 207–210
treatment of patients with, 192
intermediate potency (NHS), 98
organ perfusion studies and, 56–57
organ transplantation and, 54–56
physiological control of activity, 62–69
and platelets, 60–61
preparations given to haemophilic patients, 99
reactions of, with antibodies, 42–43
response to, following major surgery, 102
site of synthesis of, 54–62
structure and function of, **31–52**
synthesis of, in the fetus, 69–70
theoretical response to, 101
tissue culture experiments and, 57
and tissue factor, 10–11
transfusion studies in haemophilia and von Willebrand's disease, 61–62
transient changes of activities, 63
and the vascular endothelium, 58–60
Factor VIII-related activities, sustained rise of, 67–69
Factor VIII-related antigen—
and ristocetin cofactor, 46
subunits of, 46–47
Factor VIII-related substances, association of, 36–38
Factor VIII:C—
possible synthesis by the vascular endothelium, 60
vs VIIIR:Ag, 118
Factor IX, 32–36
activated, 34
SDS polyacrylamide gel electrophoresis of, 22
activity—
assays of, 83–84
Factor IX (*continued*)
in plasma, 97
recovery of, from various preparations, 98
therapeutic materials containing, 97–100
antibodies to, 109–110
concentrates, schemes for production of, 195
and factor VIII, 9–10
interaction of, 31–32
heterogeneity of, 36
inhibitors to, 210–211
NHS, 98
properties of, 33
structure and function of, **31–52**
Factor X, 90, 199
and factor V, 11–12
Factor XI, 9, 91–92, 200
and Fleaujac, Fitzgerald and Fletcher factor deficiency, 200
partial structure of human, 9
Factor XII, 6–7
partial structure of bovine, 7
Factor XIII (FSF), 87–88, 200–201
and CIg, 13
deficiency, screening tests for, 82–83
Factors II, V, VII and X, 88–90
modification of the one-stage prothrombin time for the measurement of, 88–89
Factors IX, II, X, and VII, concentrates containing, 194–198
Fibrin formation, biochemistry of, 170
Fibrinogen, 13, 199–200
congenital abnormalities of, **169–181**
defects, 87
inherited abnormalities of: tentative classification, 172–173
measurement of, in the clinical laboratory, 170–172
synthesis, treatment of disorders of, 178–179
Fletcher and Fitzgerald factors, 91, 200

GENETIC counselling, 141–142
Genotype assignment (carrier detection) in the haemophilias, **115–145**

HAEMOPHILIA—
antifibrinolytic agents in the treatment of, 99–100
carrier probability without family history, 125
centre, 103–104
delivery of therapy to the patient, 103–106
genetic counselling in, 128, 141–142
genotype assignment (carrier detection) in, **115–145**
home therapy and, 105–106

Haemophilia A, 116–132
VIII:C and VIIIR:Ag values in normals and carriers, 117–119
combining laboratory and pedigree data, 123–126
differentiation from haemophilia B, 83–84
genetic counselling and, 119
history of carrier classification, 116–117
other pedigree information, 126–128
practical hints about genotype assignment, 128–129
prevalence of possible carriers, 129
sporadic male and, 129–130
statistical treatment of laboratory data on, 119–123
use of VIIIR:Ag and VIIIR:WF in, 132
variables yet to be assessed, 130–132
Haemophilia B, 132–136
differentiation from haemophilia A, 83–84
genetic heterogeneity in, 133
Haemophilia and Christmas disease—
clinical jaundice in, 107
complications of treatment of, 106–110
prevalence of, 96–97
prophylaxis in, 106
recent advances in the management of, **95–114**
sort of concentrate to use in, 111
treatment of,
amount of factor VIII and IX needed, 110–111
pyrogenic and other reactions to, 108
and thrombosis, 108
and transmission of infective agents, 106–108
Haemophilic patient—
management of, for single episodes of bleeding, 100–103
his place in society, 113
registration, 130
Hageman factor, 91
Hepatitis B, transmission of, 201–202
Hereditary deficiencies of AT III, 19–20
Hypofibrinogenaemia, 172–173
and dysfibrinogenaemia, 175–178
differential diagnosis of, in ill patients, 177–178
in the same family, 178
treatment of, 179

INHIBITORS, natural, of blood clotting, 15–22

KALLIKREIN, 8
Kininogen, high molecular weight, 8

MIDDLE phase of coagulation, 9–12

PROPHYLAXIS in haemophilia and Christmas disease, 106
Protease inhibitors—
AT III, 16–20
other, 20
physiological role of, 20–21
Prothrombin—
defects, 89
and thrombin, 12–13

SPONTANEOUS bleeding, 100

TERMINAL phase of coagulation, 12–13
Thrombin—
and antithrombin III, 16–20
SDS electrophoresis of products of interaction of, 18
and prothrombin, 12–13
Tissue factor and factor VIII, 10–11
Traumatic bleeding, 100–103

VITAMIN K, role of, in blood coagulation, 14–15
von Willebrand's disease, 85–87, 137–141, **147–169**
'affected' group variants, 139
associated with other defects, 158
bleeding time and, 85
clinical aspects of, 158–162
diagnosis, 160–161
factor VIII coagulant activity (VIII:C) and, 86
factor VIII concentrates in, 193
factor VIII-related antigen (VIIIR:Ag) and, 86
frequency, 158–160
groups in, 139
heterogeneity of, 154
historical background, 147–149
platelet retention in glass bead columns and, 85
prognosis, 161–162
recent studies on, 149–162
reinvestigation of families with, 159
relationship between tests in, 87
response of factor VIII activity to transfusion and, 86–87
response to transfusion, 153-154
ristocetin-induced platelet aggregation and, 86
symptoms, 160
therapy, 162
type I, 155–156
type II, 156–157
type III, 157
type IV, 157–158
variants of, 138
Willebrand factor assay (VIII:WF) and, 86
'von Willebrand factor', nature and function of, 149–152

Index

Note: Page numbers of article titles are in **bold face** type.

ANAEMIA
  acute, effects of on erythrokinetics, 346–347
  aplastic, 280
  drug-induced, 328–329
  genetic, as tool for haematological research, **239–262**
  haemolytic, 254–255
  hereditary mouse, 247–257
  hypochromic, 253–254
  macrocytic, normochromic, 248–253
    mutant immune systems, 250
    W-anaemic mutants, 250–252
  protracted, effects of on erythrokinetics, 345–346
  refractory, 280
  transitory, 255–256

BLAST cells, *see* Leukaemia blast cells
B lymphocytes, **359–419**
  antigen receptors, 397
  diversity of antigen-binding sites, 397–398
  isotypes of membrane Ig, 398
  ontogeny of, 399–406
    bursa analogues in mammals, 400–401
    bursa of Fabricius in birds, 399–400
    fetal and postnatal, 401–406
    from haemopoietic stem cells, 401
  other receptors, 398–399
Bone—
  distribution of CFU-S in, 225–226
  marrow—
    cultures, cell development potential in, 455–458
    haemopoietic colony growth in, 477–481
    transplantation, sensitivity of CFU-S to, 230–231
Bursa of Fabricius, 399–400
  analogues in mammals, 400–401

CELL—
  cycle characteristics, 339–347
    disease states, 347
    effects of acute anaemia on, 346–347
    effects of protracted anaemia on, 345–346
Cell (*continued*)
  cycle characteristics (*continued*)
    effects of protracted irradiation on, 344–345
    in normal adult animals, 339–343
    in young animals, 343–344
  cycle status, detection of changes in, 425
  interactions, in vitro, **453–468**
    defective environments, 464–465
    development potential in long-term bone marrow culture, 455–458
    establishing cultures, 454–455
    evidence in vivo, 453–454
    intraspecies applications, 465–466
    role of adherent layer in haemopoiesis, 458–464
  separation, **421–434**
    cell sorters, 427–430
      applications of technology of, 430–432
      based on changes in fluorescence depolarization, 432
    rosette fractionation, 426–427
    specific affinity fractionation, 425–426
Clones, leukaemic, 510–514
Cluster-forming cells, 265
Colony stimulating factor (CSF), 265
  significance of in vivo, 290–292
Culture—
  assays for pluripotent cells, 506–507
  bone marrow, 455–458
  colony formation in, 505–506
  establishment of, 454–455
  in study of granulopoiesis kinetics, 362–365
  of leukaemic blast cells, 507–509
  techniques for GM-progenitor cells, 265–271
    cell collection, 265–267
    culture preparation, 268
    medium preparation, 267–268
    present clinical uses, 281–282
    problems of interpretation, 271–273
      dilution by peripheral blood, 271
      time of scoring of cultures, 273
      variability in culture efficiency, 271–273

Culture (*continued*)
techniques for GM-progenitor cells (*continued*)
scoring of cultures, 270–271
underlayer preparation, 268–269
Cytotoxic drugs, sensitivity of CFU-S to, 231–232

DIAMOND-BLACKFAN syndrome, 377
Down's syndrome, 376

ERYTHROCYTE precursor cells, recognizable kinetics of, **335–350**
Erythroid cell proliferation inhibitor, 437–438
Erythroid colony—
assays of in man, 324–329
characteristics of the colonies, 324–325
clonal proliferation, 327–328
drug-induced anaemia, 328–329
haemoglobin switch, 325–326
immune suppression of erythropoiesis, 328
myeloproliferation syndromes, 326–327
relationship to bone marrow activity, 326
cells forming—
early, 313–315
factors influencing, 317–321
late, 315–316
Erythroid precursor cell numbers, experimental manipulations of, 246–247
Erythroid progenitor cells, relevance of for the study of haematological disease, **311–333**
Erythrokinetics, 335–350
cell cycle characteristics, 339–347
effects of acute anaemia on, 346–347
effects of protracted anaemia on, 345–346
effects of protracted irradiation on, 344–345
in disease states, 347
in normal adult animals, 339–343
in young animals, 343–344
Erythron, structure of, 321–324
Erythropoiesis—
immune suppression of, 328
regulators of, 436–438
erythroid cell proliferation inhibitor, 437–438
erythropoietin, 436–437
Erythropoietin, 317–318, 436–437
cells responsive to, 311–313

GRANULOCYTE—
blood compartment of, 354–356
intramedullary, kinetics of, 356–358
myeloblasts, 356
myelocytes, 356–358
promyelocyte, 356
–monocyte precursors, detection and analysis of, **263–285**

Granulocyte (*continued*)
–monocyte precursors, detection and analysis of (*continued*)
agar cultures, 271–273
culture techniques for, 265–271
properties and levels of, 274–279
general variations in, 276–277
in myeloid leukaemia, 277–279
in normal humans, 274–276
negative feedback, 297–300
production, mechanisms for increasing, 359–360
Granulopoiesis—
humoral regulation of, **287–309**
ineffective, 358
kinetics of, **351–370**
blood granulocyte compartment, 354–356
cultures in vitro in study of, 362–364
diffusion chamber culture in study of, 364–365
factors affecting, 359–360
in diverse diseases, 361–362
intermedullary, 356–358
mechanisms to increase, 359–360
regulators of, 439–440
Granulopoietic colony stimulating activities, 288–290
Granulopoietic progenitor cells, 287–288

HAEMATOLOGICAL disease, relevance of erythroid progenitor cells for study of, **311–333**
Haematological research, genetic anaemias as tools for, **239–262**
Haemoglobin, 246
fetal–adult switch, 325–326
structural defects in, 257
Haemoglobinuria, paroxysmal nocturnal (PNH), 375–376
Haemopoiesis, 244–247
cell assays, 244–245
experimental manipulations of erythroid precursor cell numbers, 246–247
haemoglobins, 246
in myeloblastic leukaemia, **501–523**
colonies in culture, 505–506
culture assays for pluripotent cells, 506–507
genetic methods, 503–504
in vitro, role of adherent layer in, 458–464
lineages and programmes in, 509–510
microenvironment of, **469–500**
ageing and, 490–492
damage to, 487
definitions of, 472–475
experimental findings on, 477–486
mode of action of, 475–477
neural and chemical components suggested by, 486

Haemopoiesis (*continued*)
microenvironment (*continued*)
relation to other systems, 487–489
role of in disease states, 489–490
studies in vitro, 484–486
proliferation regulators in, **435–451**
clinical potential of, 448–450
regional restriction of, 469–472
stem cells, 472
supporting regions, 470–471
Haemopoietic dysplasias, 374–375
Haemopoietic progenitor cells, 264–265
Haemopoietic stem cells, development of B lymphocytes from, 401
Hermansky–Pudlak syndrome, 376
Higashi syndrome, 376

IMMUNOGLOBULIN, membrane, isotypes of, 398
Iron, radioactive, 336–339

KIDNEY, haemopoietic support from, 471
Kinetics—
erythrocyte precursor cell, **335–350**
granulocytopoiesis, **351–370**

LEUKAEMIA—
acute non-lymphocytic, 374–375,
development of, 514–515
granulocytic, chronic, 372–373
megakaryocytic, 375
myeloblastic, haemopoiesis in, **501–523**
myeloid, 303–304
acute, 278–279
chronic, 277
regulatory responsiveness of cells of, 300–303
Leukaemic blast cells—
culture of, 507–509
progenitors of, properties of, 516–518
Leukaemic clones, 510–514
Liver, haemopoietic support from, 470–471
Ly antigens, 405–406
Lymph nodes, haemopoietic support from, 471
Lymphocyte, **395–419**
effects of microenvironment on, 481–482
parallel diversification of, 412
resolution of diversity of, 395–396
T versus B dichotomy, 396–397
Lymphopoiesis, **395–419**

MAY–HEGGLIN anomaly, 376
Megakaryocytes, recognizable non-proliferating, 380–381
Megakaryocytopoiesis, **371–394**
regulation of, 384–387

Mouse—
laboratory, 239–244
animal care, 243–244
animal handling, 244
availability of mutants, 257
hereditary anaemias in, 247–257
inbred strains, 240–242
mutations of, 242–243
Sl/Sl^d, 482
Myeloblasts, 356
Myelocytes, 356–358
Myelofibrosis, 280
with myeloid metaplasia (MMM), 373
Myelopoiesis, dualistic regulatory role of monocytes and macrophages in, 193–297
Myeloproliferative syndromes, 279–281, 326–327

PERITONEAL cavity, haemopoietic support from, 471
Platelets, blood, 381–383
distribution of, 381
regulation of production of, 384–387
megakaryocytic response, 384–385
non-thrombocytopenic stimulation, 386–387
thrombopoietin, 385–386
size of, 382–383
survival of, 381–382
Polycythaemia vera, 280, 373
Preleukaemia, 280–281
Promyelocytes, 356

RADIATION—
protracted, effects of on erythrokinetics, 344–345
sensitivity of CFU-S to—
acute partial body, 230
acute whole body, 229–230
continuous, 232–233
Rosette fractionation, 426–427

Sl/Sl^d MOUSE, haemopoietic microenvironment and, 482
Spleen—
colony-forming unit (CFU-S), 222–234
distribution of in bones, 225–226
mobilization of, 226
physical separation of stem cells, 224–225
response to perturbations, 229–233
self-renewing capacity of, 228–229
turnover of, 227–228
haemopoietic colony growth, 477–481
location of, 479
Stem cell—
–CFC-S relationship, 233–234
diploid, 377–379
haemopoietic support from, 472

Stem cell (*continued*)
multipotential haemopoietic, 264
physical separation of, 224–225
pluripotent, **221–237**
culture of, 506–507
dysfunction of, 371–377
acute non-lymphocytic leukaemia, 374–375
chronic granulocytic leukaemia, 372–373
Down's syndrome, 376
haemopoietic dysplasias, 374–375
megakaryocytic leukaemia, 375
myelofibrosis with myeloid metaplasia, 373
paroxysmal nocturnal haemoglobinuria, 375–376
polycythaemia vera, 373
primary thrombocythaemia, 373–374
polyploid, 379
regulation of proliferation of, 440–448
local control of, 440–441
mode of action of, 444–448
modifiers in haemopoietic tissue, 441–443
source of regulatory factors, 443–444
Surface markers, **421–434**
detection of, 423–425
Surface markers (*continued*)
detection of (*continued*)
changes in cell cycle status, 425
immunochemical, 423–424
through cytoplasmic changes, 424–425
non-specific, 423
of haemopoietic cells, 430–431
specific for a class of cell, 422
specific for a level of development, 422
specific for a regulatory mechanism, 422
specific for a type of cell, 422

T CELLS, 319–320, **395–419**
helping and suppressive actions of, 405
Ia antigens, 406–407
Ly antigen, 405–406
ontogeny of, 408–411
progenitors of thymocytes, 409–411
thymic cells, 408–409
Thalassaemia, 256
Thrombocythaemia, primary (PT), 373–374
Thrombopoietin, 385–386
Thymocytes, 408–409
progenitors of, 409–411

W-ANAEMIC mutants, 250–252
Wiskott–Aldrich syndrome, 377